Acceptable for general use within NHS Scotland as an additional treatment for the secondary prevention of myocardial infarction.
Whilst cost effectiveness appears to be within generally acceptable limits, NHS Boards will recognise that there are now a number of established interventions for this indication. The priority given to this agent needs to be considered alongside the implementation of other effective approaches to secondary prevention of cardiovascular disease, always keeping in mind alternative dietary methods of obtaining fish oil supplementation.
Download detailed advice21KB (PDF)
- Medicine name:
- Omega-3-acid ethyl esters for (Omacor)
- SMC ID:
- Secondary prevention of myocardial infarction
- Pharmaceutical company
- Solvay Healthcare Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Date advice published
- 08 November 2002